Abstract:Objective: The expression of connective tissue growth factor mRNA in human kidneys may serve as an early marker for lupus nephritis progression. Therefore, we speculated that connective tissue growth factor may be involved in the pathogenesis of systemic lupus erythematosus and lupus nephritis. In this study, we set out to investigate the associations between serum connective tissue growth factor levels and clinicopathological features of patients with systemic lupus erythematosus and lupus nephritis. Methods: Serum samples from patients with non-renal systemic lupus erythematosus, renal biopsy-proven lupus nephritis and healthy control subjects were detected by enzyme-linked immunosorbent assay for serum connective tissue growth factor levels. The associations between connective tissue growth factor levels and clinicopathological features of the patients were further analysed. Results: The levels of serum connective tissue growth factor in patients with non-renal systemic lupus erythematosus and lupus nephritis were both significantly higher than those in the normal control group (34.14 ± 12.17 ng/ml vs. 22.8 ± 3.0 ng/ml, p<0.001; 44.1 ± 46.8 ng/ml vs. 22.8 ± 3.0 ng/ml, p = 0.035, respectively). There was no significant difference of the serum connective tissue growth factor levels between non-renal systemic lupus erythematosus and lupus nephritis group (34.14 ± 12.17 ng/ml vs. 44.1 ± 46.8 ng/ml, p = 0.183). Serum connective tissue growth factor levels were significantly higher in lupus nephritis patients with the following clinical manifestations, including anaemia (51.3 ± 51.4 ng/ml vs. 23.4 ± 9.7 ng/ml, p<0.001) and acute renal failure (85.5 ± 75.0 ng/ml vs. 31.2 ± 21.8 ng/ml, p = 0.002). Serum connective tissue growth factor levels in class IV were significantly higher than that in class II, III and V (57.6 ± 57.5 ng/ml vs. 18.7 ± 6.4 ng/ml, p = 0.019; 57.6 ± 57.5 ng/ml vs. 25.2 ± 14.9 ng/ml, p = 0.006; 57.6 ± 57.5 ng/ml vs. 30.5 ± 21.3 ng/ml, p = 0.017, respectively). Serum connective tissue growth factor levels were significantly higher in those with both active/chronic lesions than those in those with active lesions only in either class IV (84.9 ± 69.6 ng/ml vs. 40.0 ± 40.2 ng/ml, p = 0.001) or in combination of class III and IV lupus nephritis (63.3 ± 63.4 ng/ml vs. 38.3 ± 37.9 ng/ml, p = 0.035, respectively). Serum connective tissue growth factor levels were negatively associated with estimated glomerular filtration rate (r = −0.46, p<0.001) and positively associated with interstitial inflammation (r = 0.309, p = 0.002) and interstitial fibrosis (r = 0.287, p = 0.004). Serum connective tissue growth factor level was a risk factor for doubling of serum creatinine in lupus nephritis ( p<0.001, hazard ratio = 1.015, 95% confidence intervals 1.008–1.022) in univariate analysis. Conclusions: Serum connective tissue growth factor levels were significantly higher in lupus and correlated with chronic renal interstitial injury and doubling of serum creatinine in patients with lupus nephritis.

Renal tubular and glomerular estrogen receptor ß levels are lower in lupus nephritis than in familial Mediterranean fever-associated renal amyloidosis

FRI0226 LOW EXPRESSION OF ESTROGEN RECEPTOR BETA IN RENAL TUBULAR EPITHELIAL CELL MAY CONTRIBUTE TO HYPERURICEMIA IN PREMENOPAUNITED STATES OF AMERICAL FEMALE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Low expression of estrogen receptor β in renal tubular epithelial cells may cause hyperuricemia in premenopausal patients with systemic lupus erythematosus

Estrogen Receptor α Signaling Exacerbates Immune-Mediated Nephropathies through Alteration of Metabolic Activity

FRI0391 The relationship between oestrogen receptors and hyperuricemia in young female systemic lupus erythematosus patients

Low expression of estrogen receptor β in T lymphocytes and high serum levels of anti-estrogen receptor α antibodies impact disease activity in female patients with systemic lupus erythematosus

Estrogen receptor alpha modulates mesangial cell responses to toll-like receptor ligands

Characteristics and Renal Survival of Patients with Lupus Nephritis with Glomerular Immunoglobulin G4 Deposition: a Single-Centre Retrospective Analysis.

Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity

Estrogen receptor gene polymorphism and its association with clinicopathological manifestation of lupus nephritis

Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis

Shedding of Endothelial Protein C Receptor Contributes to Vasculopathy and Renal Injury in Lupus: in Vivo and in Vitro Evidence

Serum level of anti-α-enolase antibody in untreated systemic lupus erythematosus patients correlates with 24-hour urine protein and D-dimer

Urinary Albumin Levels Are Independently Associated with Renal Lesion Severity in Patients with Lupus Nephritis and Little or No Proteinuria

Sex Differences in Estrogen Receptor Gene Polymorphism and Its Association with Lupus Nephritis in Chinese

Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis.

Levels of serum IL-18 and IL-34 in patients with lupus nephritis and their significance

The Serum Levels of Connective Tissue Growth Factor in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Urinary Modified C-Reactive Protein is Closely Associated with Tubulointerstitial Lesions in Lupus Nephritis.

Serum Uric Acid Combined with Homocysteine as a Predictive Biomarker of Lupus Nephritis

Serum Renalase Levels Correlate With Disease Activity In Lupus Nephritis